This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
by Zacks Equity Research
Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
by Zacks Equity Research
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development
by Zacks Equity Research
Waters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor.
Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock
by Zacks Equity Research
Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe
by Zacks Equity Research
Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy
by Zacks Equity Research
Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
by Zacks Equity Research
IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.
Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication
by Zacks Equity Research
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
by Zacks Equity Research
Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.
Sanofi (SNY) Gets FDA Nod for Rare Disease Drug Xenpozyme
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
by Zacks Equity Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.
Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study
by Zacks Equity Research
Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.
Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.